Bullous pemphigoid: Rituximab to the rescue?

It is not my imagination—the incidence of bullous pemphigoid (BP) is increasing in my practice. This is a function of an aging population in concert with more drug-induced cases, notably with dipeptidyl peptidase IV inhibitors and anti–PD-1/PD-L1 agents. Treating BP is challenging—although corticosteroids are the bedrock of therapy, every effort is made to administer steroid-sparing medications. Options include dapsone, doxycycline, niacinamide,...